Výsledky vyhledávání - "Jose Guillen-Rodriguez"

Abstract P065: Effects of metformin on breast tissue inflammation in premenopausal women with components of metabolic syndrome

Autor: Liane E. Pinto, Sara Centuori, Jose Guillen-Rodriguez, Denise J. Roe, Edgar Tapia, Pavani Chalasani, H-H. Sherry Chow

Publikováno v: Cancer Prevention Research. 16:P065-P065

Background: Obesity, with increasing worldwide prevalence, is associated with increased breast cancer burden. The association is attributed to multiple metabolic disturbances including chronic inflammation due to dysfunctional adipose tissue. Feature

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::abef3ca316b3017ea331b423e46748da
https://doi.org/10.1158/1940-6215.precprev22-p065

Zobrazit plný text záznamu

Randomized Crossover Trial Evaluating Detoxification of Tobacco Carcinogens by Broccoli Seed and Sprout Extract in Current Smokers

Autor: Julie E. Bauman, Chiu-Hsieh Hsu, Sara Centuori, Jose Guillen-Rodriguez, Linda L. Garland, Emily Ho, Megha Padi, Vignesh Bageerathan, Lisa Bengtson, Malgorzata Wojtowicz, Eva Szabo, H.-H. Sherry Chow

Publikováno v: Cancers; Volume 14; Issue 9; Pages: 2129

Consumption of cruciferous vegetables, rich in the isothiocyanate glucoraphanin, is associated with reduced risk of tobacco-related cancers. Sulforaphane, released by hydrolysis of glucoraphanin, potently induces cytoprotective phase II enzymes. Sulf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f6e30e102e8ddc9022a628a3e5cab29
https://doi.org/10.3390/cancers14092129

Zobrazit plný text záznamu

A Phase II, Open-Label Study of Bortezomib (Velcade®), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Autor: Abhijeet Kumar, Jose Guillen-Rodriguez, Jonathan H. Schatz, Lora Inclan, Alfonso E Ayala, Xavier Rivera, Srinath Sundararajan, Faiz Anwer, Daruka Mahadevan, Daniel O. Persky, Soham D. Puvvada

Publikováno v: Blood. 128:1790-1790

Background: Mantle cell lymphoma (MCL) is characterized by initial sensitivity to both chemotherapy and radiation but also by an invariable relapse and eventual resistance to treatment. Bortezomib (Velcade) is a proteasome inhibitor and is approved a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aa792b3b1ccf8c9a221c10d62a6dc647
https://doi.org/10.1182/blood.v128.22.1790.1790

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání